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GUEST EDITORIAL
The exponential rise in cancer costs in South Africa (SA) was 
illustrated in a recent Sunday Times article entitled ‘The cost of 
cancer can be a debt sentence’.[1] Our minister of health talks of a ‘war’ 
against the high costs of cancer drugs, and epidemiologists project 
a sharply rising incidence. Eminent international medical journals, 
such as The Lancet, underline the fact that cancer cost is a growing 
international problem that confronts even the richest countries. 
Indeed, the question may be posed: if richer countries in the world 
are battling to cover the costs of cancer, what is the prognosis for SA?
The future incidence of cancer
Epidemiologists predict a major increase in cancer in the developing 
world, with 60% of all new cases coming from Africa, Asia and South/
Central America.[2] In SA the projected increase is even greater, and 
a recent article in The Lancet[3] projected a 78% increase by 2030. 
Rapidly changing lifestyles, uncontrolled urbanisation, pollution, 
population ageing, endemic viral infection (HBV/HIV/HPV) and an 
epidemic of obesity provide a lethal cocktail of infectious and lifestyle 
cancer risk factors in SA.[4,5]
International trends in cancer cost
The cost of healthcare is a growing international problem. In the USA 
~62% of all personal bankruptcies (2007) were caused by healthcare 
costs.[2] The cost of cancer management has ‘skyrocketed’, as illustrated 
in the European Union, which recorded a cost (in SA terms) of more 
than ZAR2 500 billion in 2009 that included direct healthcare costs, lost 
productivity and loss of family savings.[6] It appears that the doctrine of 
justum pretium (‘a fair price’) has been ignored by the pharmaceutical 
sector. Of the 12 drugs approved by the Food and Drug Administration 
in the USA for various cancer indications in 2012, 11 were priced 
above ZAR1.5 million per patient per year.[7] At the 2015 American 
Society of Clinical Oncology annual meeting, Dr Leonard Saltz wryly 
commented that ipilumumab (immune checkpoint inhibitor) was 
almost ‘4 000 times the cost of gold’.
SA cancer cost squeeze
Cancer management programmes in SA are threatened by a cost 
squeeze caused by a constrained gross domestic product in the 
face of a simultaneous increase in incidence and cost. Just recently, 
the Sandton Oncology Centre complained that, although the cost 
of cancer drugs was high, they often only make up a fraction of 
the total cost. Costs such as surgery, inpatient care, consultations 
and repetitive diagnostic and staging investigations have ratcheted 
up expenses exponentially. Because of these costs, medical aid 
limits are increasingly unable to cover even older-generation 
therapies, let alone more targeted interventions. The provision of 
new-generation immunotherapy drugs such as ipilumumab has a 
price tag of ZAR1 million, and trastuzumab costs ZAR25 000 per 
treatment. A mastectomy plus trastuzumab costs ZAR500 000, and 
immunotherapy for metastatic melanoma ~ZAR1 million.
SA private cancer healthcare
Providing healthcare cover for cancer is a high-risk business. A 
PricewaterhouseCoopers survey of the industry indicated escalating 
hospital and specialist costs, an ageing risk profile and an increase 
in unhealthy members. General agreement in this sector is that 
innovative thinking is needed to embrace new technology combined 
with a preventive approach, as well as lower the cost of drugs. 
Without these changes, a typical medical aid cover of ZAR200 000 - 
400 000 will be increasingly inadequate to cover conservative cancer 
management programmes, let alone newer-generation therapies.
SA public healthcare and cancer cost
The projected cost squeeze could preclude the public healthcare sector 
from providing even the most cost-effective treatment programmes. 
An example is radiotherapy, which is routinely provided to ~50% 
of all patients diagnosed with cancer.[8] Currently, the public sector 
has <1 linear accelerator (0.4) per million people compared with the 
recommended minimum of at least 1 per million as per International 
Atomic Energy Agency (IAEA) and World Health Organization 
(WHO) guidelines and 3 per million as per the Econex report. [9] 
Significant shortfalls are even more pronounced in the poorer provin-
ces, explaining the current delays for patients accessing radiotherapy. 
In addition, 25% of the country’s oncologists are required to 
service more than 75% of the population, contributing to a general 
shortage of oncology healthcare staff in the public healthcare sector, 
including medical physicists, radiotherapists, oncologists and trained 
nurses. A  combination of long treatment delays, limited resources, 
differentially skilled personnel, high patient volumes and advanced 
disease stage on presentation makes for a challenging environment 
to deliver optimal cancer care outcomes.[10,11] What will happen if the 
incidence of cancer increases by 78%?
A strategic rethink
Interdisciplinary planning is necessary to commercialise new 
diagnostic, surgical, radiotherapy and pharmaceutical technologies 
that can diagnose and treat cancer at an early stage. At the same time, 
efficient and cost-effective treatment can leverage the maximum out 
of the current resources. Public-private partnerships must also be 
explored to take advantage of better infrastructural capacity in the 
private sector, and a national strategic cancer control plan should be 
developed by all stakeholders to ensure the development of legislative 
(e.g. alcohol, sugar, smoking), educational (e.g. smoking, diet, 
exercise) and prophylactic (e.g. HBV/HPV vaccination) programmes. 
The development of better databases, and training of and incentives 
for oncology personnel, should be a national priority from primary 
to specialist level.[8] The retention of oncologists in the public sector 
institutions could also be prioritised and include compulsory service 
for newly qualified specialists, tagged with incentives to stay in the 
public sector. In addition, oncology exposure at undergraduate level 
needs to be improved so that primary care physicians are better 
equipped to make an early diagnosis of cancer.
The cost benefit of national screening programmes for common 
malignancies can also be explored beyond cervical cancer and a 
standardised treatment plan for pre-malignant lesions developed. 
A public sector capital investment in radiotherapy infrastructure 
such as simulators, linear accelerators and brachytherapy units in 
accordance with WHO and IAEA guidelines, together with necessary 
maintenance contracts, will obviate delays in patients accessing 
radiotherapy in the curative and palliative context. Palliative care 
facilities and trained personnel also need to be urgently developed to 
manage terminally ill cancer patients.
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Interdisciplinary research funding in SA needs to be encouraged 
in order to better understand the demographic and molecular 
aetiology of cancer in the country. Emerging opportunities supported 
by the National Research Foundation and the Medical Research 
Council are increasingly encouraging collaborative research in the 
BRICS countries (Brazil,  Russia,  India,  China  and  South Africa) or 
developed/developing country research partnerships.
The cost of cancer drugs is multi-tiered. At present, they are more 
expensive in developed countries such as the USA and differ entially 
discounted in developing countries. Nevertheless, the dis counted price of 
new-generation cancer drugs is still unaffordable in developing countries 
and especially in sub-Saharan Africa.[12] The reduction of these costs is an 
international issue that must precipitate government and NGO lobbies 
in international forums to allow SA to adopt a patent bypass approach 
(as in India), or alternatively to reduce differential pricing even further. 
In parallel, there is a need to keep looking at making more efficient use 
of budget allocations for drugs, with many oncologists continuing to 
prescribe two to three lines of chemotherapy in very advanced stages, and 
requesting repeated costly investigations because of the fear of litigation.
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